同和药业(300636) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period reached CNY 86,221,294.33, a 40.02% increase year-on-year[7] - Net profit attributable to shareholders increased by 132.06% to CNY 15,076,295.46 for the reporting period[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 238.92% to CNY 14,930,603.82[7] - Basic earnings per share increased by 130.91% to CNY 0.1875[7] - Total operating revenue for Q3 2019 was CNY 86,221,294.33, an increase of 40.06% compared to CNY 61,575,807.45 in the same period last year[42] - Net profit attributable to the parent company for Q3 2019 was CNY 219,919,081.21, an increase of 21.05% from CNY 181,719,817.81 in the previous year[40] - The total operating revenue for the year-to-date period was CNY 281,253,571.61, compared to CNY 187,395,780.57 in the previous year, representing a growth of approximately 50%[49] - The total profit for Q3 2019 was CNY 46,656,625.93, which is a 64.2% increase from CNY 28,453,348.38 in Q3 2018[51] Assets and Liabilities - Total assets increased by 16.51% to CNY 936,291,813.76 compared to the end of the previous year[7] - Total assets as of September 30, 2019, amounted to CNY 933,317,021.19, compared to CNY 799,937,241.57 at the end of 2018, reflecting a growth of 16.67%[38] - Total liabilities increased to CNY 237,468,629.05 in Q3 2019 from CNY 144,428,339.49 in the same period last year, representing a rise of 64.55%[39] - The company reported a total equity of CNY 695,848,392.14, an increase from CNY 655,508,902.08 year-over-year[40] Cash Flow - The net cash flow from operating activities for the year-to-date was negative CNY 10,627,464.66, a decrease of 118.07%[7] - The cash flow from operating activities showed a net outflow of CNY 10,627,464.66, a significant decrease from a net inflow of CNY 58,813,299.97 in the same quarter last year[59] - The net cash flow from investing activities decreased by 104.11% to -111,579,733.39 yuan, mainly due to a significant reduction in the scale of idle fund investments[21] - The net cash flow from financing activities increased by 605.07% to 94,620,633.44 yuan, primarily due to new bank financing[21] - The company's cash and cash equivalents decreased by 64.98% to ¥13,960,106.23 from ¥39,867,298.35, largely due to significant payments for engineering and equipment[18] - The company's cash and cash equivalents decreased to CNY 13,649,138.65 from CNY 32,348,578.25, a decline of 57.73%[37] - The ending balance of cash and cash equivalents was 8,188,969.90 CNY, down from 5,211,235.80 CNY in the previous year[64] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,002[11] - The top shareholder, Pang Zhengwei, holds 19.61% of the shares, with 15,872,921 shares, of which 15,081,081 are pledged[11] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 2,423,153.23 during the reporting period[8] - Other income decreased by 69.82% to ¥2,423,153.23, mainly due to a reduction in government subsidies received[20] - The company reported a significant increase in other income, totaling CNY 52,127.00, compared to CNY 43,800.45 in the previous year[51] Costs and Expenses - Operating costs increased by 45.15% to ¥195,396,849.31 from ¥134,613,204.80 year-on-year, primarily due to the rise in business revenue[20] - The company reported a 113.55% increase in income tax expenses to ¥4,775,425.15, driven by higher profits during the period[20] - The total operating costs for Q3 2019 were CNY 70,487,572.81, up 22.87% from CNY 57,358,492.78 in Q3 2018[42] - The total operating costs for the year-to-date period were CNY 238,751,049.59, compared to CNY 173,200,889.33 in the previous year, indicating an increase of about 37.9%[49] - Financial expenses surged by 295.98% to ¥1,247,897.71, attributed to increased loan interest from bank financing[20] - Research and development expenses for the third quarter amounted to CNY 7,834,672.29, compared to CNY 6,478,512.91 in the previous year, indicating a rise of approximately 20.9%[46] - Research and development expenses increased to CNY 19,295,518.54, up from CNY 15,806,396.43, indicating a focus on innovation[55]